BioCryst Pharmaceuticals, Inc. (BCRX)
USD 7.31
(-2.4%)
USD 7.31
(-2.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -95.14 Million | -161.85 Million | -142.15 Million | -137.21 Million | -89.58 Million | -92.56 Million |
| Net Income | -226.53 Million | -247.11 Million | -184.06 Million | -182.81 Million | -108.89 Million | -101.25 Million |
| Depreciation & Amortization | 1.65 Million | 1.43 Million | 777 Thousand | 748 Thousand | 724 Thousand | 770 Thousand |
| Deferred income taxes | 22.47 Million | - | -55.84 Million | 753 Thousand | 464 Thousand | 1.16 Million |
| Stock-based compensation | 55.61 Million | 44.7 Million | 34.64 Million | 14.79 Million | 17.71 Million | 9.39 Million |
| Change in working capital | -32.4 Million | -58.94 Million | 8.12 Million | 26.87 Million | -872 Thousand | -3.53 Million |
| Other non-cash items | 84.05 Million | 98.07 Million | 54.2 Million | 2.42 Million | 1.27 Million | 885 Thousand |
| Investing Cash Flow | -131.49 Million | -128.23 Million | 15.8 Million | -6.85 Million | 77.93 Million | 4.76 Million |
| Investments in PPE | -2.16 Million | -1.35 Million | -2.38 Million | -514 Thousand | -343 Thousand | -366 Thousand |
| Acquisitions | 2.16 Million | 1.35 Million | 2.38 Million | 513 Thousand | 366 Thousand | 366 Thousand |
| Investment purchases | -514.4 Million | -244.28 Million | -10.01 Million | -49.81 Million | -3.01 Million | -62.61 Million |
| Sales/Maturities of investments | 385.07 Million | 117.39 Million | 28.2 Million | 43.47 Million | 81.29 Million | 67.74 Million |
| Other Investing Activities | -2.16 Million | -1.35 Million | -2.38 Million | -513 Thousand | -366 Thousand | -366 Thousand |
| Financing Cash Flow | 32.48 Million | 88.02 Million | 359.66 Million | 302.69 Million | 99.09 Million | 62.5 Million |
| Debt repayment | -27.14 Million | -73.07 Million | -293.87 Million | -52.42 Million | -19.47 Million | -4.02 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 8.68 Million | 14.95 Million | 50 Million | 93.27 Million | 58.5 Million | 53.4 Million |
| Other Financing Activities | 50.94 Million | 146.14 Million | 309.66 Million | 261.83 Million | 60.07 Million | 13.12 Million |
| Accounts receivables | -6.09 Million | -21.47 Million | -23.8 Million | 18.52 Million | -16.16 Million | 568 Thousand |
| Accounts payables | -16.8 Million | -22.36 Million | 39.41 Million | 17.35 Million | 11.74 Million | 4.48 Million |
| Inventory | -1.45 Million | -12.42 Million | -8.76 Million | -7.03 Million | 1.64 Million | -1.64 Million |
| Other working capital | -8.05 Million | -2.69 Million | 1.28 Million | -1.97 Million | 1.89 Million | -6.93 Million |
| Cash at beginning of period | 306.23 Million | 507.73 Million | 274.34 Million | 115.72 Million | 28.27 Million | 53.56 Million |
| Cash at end of period | 112.44 Million | 306.23 Million | 507.73 Million | 274.34 Million | 115.72 Million | 28.27 Million |
| Capital Expenditure | -2.16 Million | -1.35 Million | -2.38 Million | -514 Thousand | -343 Thousand | -366 Thousand |
| Effect of forex changes on cash | 362 Thousand | 566 Thousand | 71 Thousand | - | - | - |
| Net cash flow / Change in cash | -193.79 Million | -201.49 Million | 233.38 Million | 158.62 Million | 87.44 Million | -25.29 Million |
| Free Cash Flow | -97.3 Million | -163.2 Million | -144.54 Million | -137.73 Million | -89.92 Million | -92.93 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -14.03 Million | -12.67 Million | -35.37 Million | -226.53 Million | -61.73 Million | -36.14 Million |
| Depreciation & Amortization | -8.4 Million | 320 Thousand | 306 Thousand | 1.65 Million | 423 Thousand | 420 Thousand |
| Deferred income taxes | - | - | - | 22.47 Million | 475 Thousand | -12.73 Million |
| Stock-based compensation | 17.24 Million | 13.17 Million | 13.65 Million | 55.61 Million | 16.48 Million | 12.27 Million |
| Change in working capital | 66.81 Million | -18.29 Million | -48.52 Million | -32.4 Million | 18.1 Million | -16.19 Million |
| Other non-cash items | -52.98 Million | 49.56 Million | 19.44 Million | 84.05 Million | 17.32 Million | 32.48 Million |
| Investing Cash Flow | 8.48 Million | -2.44 Million | 28.75 Million | -131.49 Million | -28.47 Million | 23.11 Million |
| Investments in PPE | 390 Thousand | -155 Thousand | -235 Thousand | -2.16 Million | -554 Thousand | -987 Thousand |
| Acquisitions | - | - | - | 2.16 Million | 5.37 Million | -24.1 Million |
| Investment purchases | -26.93 Million | -112.29 Million | -88 Million | -514.4 Million | -156.98 Million | -123.88 Million |
| Sales/Maturities of investments | 35.48 Million | 110 Million | 117 Million | 385.07 Million | 129.06 Million | 147.99 Million |
| Other Investing Activities | -449 Thousand | -2.29 Million | -235 Thousand | -2.16 Million | 1.00 | 24.1 Million |
| Financing Cash Flow | 872 Thousand | -1.56 Million | -1.04 Million | 32.48 Million | -3.17 Million | 1.22 Million |
| Debt repayment | -556 Thousand | -402 Thousand | -390 Thousand | -27.14 Million | -1.16 Million | -262 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -258 Thousand | 276 Thousand | 11 Thousand | 8.68 Million | 164 Thousand | 1.48 Million |
| Other Financing Activities | 1.68 Million | -1.84 Million | -2.35 Million | 50.94 Million | -2.17 Million | -262 Thousand |
| Accounts receivables | -3.31 Million | -8.24 Million | -3.83 Million | -6.09 Million | -2.97 Million | 3.84 Million |
| Accounts payables | -2.83 Million | -12.53 Million | -44.56 Million | -16.8 Million | 19.87 Million | -15.31 Million |
| Inventory | 1.84 Million | 739 Thousand | -1.22 Million | -1.45 Million | 907 Thousand | -3.38 Million |
| Other working capital | -2.85 Million | 1.74 Million | 1.1 Million | -8.05 Million | 291 Thousand | -1.34 Million |
| Cash at beginning of period | 80.2 Million | 86.13 Million | 112.44 Million | 306.23 Million | 152.48 Million | 147.78 Million |
| Cash at end of period | 99.06 Million | 80.2 Million | 86.13 Million | 112.44 Million | 112.44 Million | 152.48 Million |
| Capital Expenditure | 390 Thousand | -155 Thousand | -235 Thousand | -2.16 Million | -554 Thousand | -987 Thousand |
| Effect of forex changes on cash | 851 Thousand | -143 Thousand | -340 Thousand | 362 Thousand | 522 Thousand | 253 Thousand |
| Net cash flow / Change in cash | 18.85 Million | -5.92 Million | -26.31 Million | -193.79 Million | -40.04 Million | 4.7 Million |
| Free Cash Flow | 9.03 Million | -1.92 Million | -53.91 Million | -97.3 Million | -9.47 Million | -20.88 Million |
RWWI
AVROIND
JUBLINGREA
EEGUF
MTO
INPST